Supplementary Materials
The PDF file includes:
- Fig. S1. Transcriptomic expression of TOP1 and MDR1 genes in PDX models.
- Fig. S2. Expression of SLFN11 in TGCA TNBC.
- Fig. S3. HR-mediated repair and DNA damage checkpoint activation in response to TOPI and TOPII inhibitors.
- Table S1. Comparison of cisplatin and irinotecan responses in 20 PDXs.
- Table S2. Characteristics of the 250 TNBCs.
- Table S3. Multivariate COX analysis of OS for SLFN11 mRNA expression in the series of 250 TNBCs.
Other Supplementary Material for this manuscript includes the following:
- Data file S1 (Microsoft Excel format). Clinical and pathological characteristics of the TNBCs corresponding to PDXs.
- Data file S2 (Microsoft Excel format). Characteristics of TNBC PDXs (BRCAness, BRCA1/2 mutations, RB1, and SLFN11 status).
- Data file S3 (Microsoft Excel format). List of genes differentially expressed between PDXs in the “response group (R)” as compared to “progressive disease (PD)” group.
- Data file S4 (Microsoft Excel format). Individual data points.
